In the following video, Motley Fool health-care analyst Max Macaluso takes a question from a Fool reader, who writes, "How do you think the initial sales of Arena Pharmaceuticals' (ARNA +0.00%) Belviq will be?"
Ask a Fool: What Will Belviq's Launch Do for Arena?
By Max Macaluso – Jun 26, 2013 at 5:35PM
NASDAQ: ARNA
Arena Pharmaceuticals
Could Arena Pharmaceuticals' new obesity drug Belviq be facing headwinds right from the start?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo
Read Next
